{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-029405","form_type":"8-K","ticker":"SCYX","cik":"0001178253","company_name":"SCYNEXIS INC","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.140632+00:00","generated_at":"2026-06-23T23:44:22.641599+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"SCYNEXIS Q2 net loss $13.3M, revenue $1.3M; cash runway into Q1 2024","bullets":["BREXAFEMME net revenue $1.3M in Q2 2022, up 86% from $0.7M in Q1.","Net loss $13.3M ($0.31/shr) vs net gain $1.7M ($0.06/shr) in Q2 2021.","Cash $118.7M at June 30, 2022; projected runway into Q1 2024.","FDA accepted sNDA for BREXAFEMME in recurrent VVC; PDUFA date Nov 30, 2022.","Total prescriptions up 29% QoQ to ~5,141; >2,200 HCPs prescribed in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-029405","json":"https://secwatch.observer/filing/0001564590-22-029405.json","markdown":"https://secwatch.observer/filing/0001564590-22-029405.md","text":"https://secwatch.observer/filing/0001564590-22-029405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178253/000156459022029405/0001564590-22-029405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178253/000156459022029405/scyx-8k_20220815.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:44:22.641599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}